WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

Tags:   Preclinical   CAR-T   ASH  

Platform demonstrates curative treatment of T-cell cancers using fratricide-resistant UCART in preclinical models

ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform. The data from this study, which was led by researchers from the Washington University in St. Louis, demonstrated efficacy in preclinical mouse models and was presented in an oral and poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego.

"An off-the-shelf allogeneic CAR-T cell therapy could be a game changer for the treatment of T-cell cancers," says John McKearn, Ph.D., CEO and President of WUGEN. "These presentations provide insight into how to solve the challenges and limitations in current CAR-T therapies. The compelling findings advance our understanding of how to improve patient outcomes for those with T cell malignancies."

---

---

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long Acting Interleukin-7 Combination Therapy (Abstract #340)

Overview and results, presented by Karl W. Staser, Ph.D., Washington University of St. Louis, include:

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor Killing (Abstract #2199)

Overview and results, presented by Matt L. Cooper, Ph.D., Washington University of St. Louis, include:

About WUGEN

WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugen.com.

---

---

For media inquiries contact: David Schull or Travis KruseRusso Partners858-717-2310212-845-4272david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com

SOURCE WUGEN Inc.

http://www.wugen.com

More news releases in similar topics

You just read:

News provided by

Dec 03, 2018, 08:00 ET

Share this article

Share this article